(Rewrites throughout with details on the licensing deal and Novavax’s earnings) PARIS, May 10 (Reuters) – Novavax on Friday erased doubts about its ability to remain in business and struck a licensing deal worth up to $1.2 billion with Sanofi for COVID-19 vaccines in exchange for a stake that doubles the U.S. drugmaker’s market value. […]